
- Alkem Lab’s net income for the third quarter was 6.26 billion rupees, marking a 5.2% increase year-over-year and closely aligning with the estimated 6.28 billion rupees.
- Revenue reached 33.7 billion rupees, which is a 1.5% increase from the previous year, but fell short of the estimated 34.87 billion rupees.
- Total costs amounted to 27.4 billion rupees, up by 1.1% compared to the previous year.
- Finance costs surged by 42%, totaling 360.3 million rupees, surpassing the estimate of 236.7 million rupees.
- Employee benefits expenses increased by 9.3% to 6.25 billion rupees, slightly under the estimated 6.29 billion rupees.
- Other income slightly decreased by 0.7%, totaling 929.9 million rupees.
- The dividend per share was reported at 37 rupees.
- Analyst recommendations included 10 buy ratings, 8 hold ratings, and 5 sell ratings.
Alkem Laboratories Ltd on Smartkarma
Analyst coverage of Alkem Laboratories Ltd on Smartkarma, a platform for independent investment research, is provided by Brian Freitas. In his report titled “India: Positioning on Stocks with Potential Passive Inflows in November,” Freitas discusses the potential inclusion of Alkem Laboratories in global passive portfolios. Along with other companies like Adani Energy Solutions and Kalyan Jewellers, Alkem Laboratories has seen an uptrend in its stock price recently, increasing the likelihood of being included in passive portfolios. Freitas notes that positioning varies across these stocks and suggests pair trades to manage market risk and capture alpha.
A look at Alkem Laboratories Ltd Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Alkem Laboratories Ltd, a pharmaceutical company focusing on generic and branded pharmaceuticals, seems to have a promising long-term outlook based on its Smartkarma Smart Scores. With a solid score of 4 for Dividend and Resilience, the company demonstrates strength in its ability to weather market fluctuations and provide consistent returns to shareholders over time. Additionally, Alkem scores a respectable 3 in terms of Value, indicating that the company may be trading at a reasonable price relative to its intrinsic worth. These scores collectively suggest that Alkem Laboratories Ltd could be a stable investment option for those seeking reliable dividends and a resilient business model.
While Alkem Laboratories Ltd shows room for improvement in terms of Growth and Momentum with scores of 3, its overall outlook appears positive given its strong performance in other key areas. As a company that also offers nutraceuticals, functional foods, health foods, and herbal products, Alkem seems to have a diverse product portfolio that could help support its long-term growth potential. Investors looking for a pharmaceutical company with a balanced mix of stability and growth prospects may find Alkem Laboratories Ltd to be an appealing choice based on its current Smartkarma Smart Scores.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
π‘ Before itβs here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- β Unlimited Research Summaries
- β Personalised Alerts
- β Custom Watchlists
- β Company Analytics and News
- β Events & Webinars